CoChat
Sign Up
Cited by 63

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Assessing clonal haematopoiesis: clinical burdens and benefits of diagnosing myelodysplastic syndrome precursor states

Gondek, Lukasz P, DeZern, Amy E·2020·The Lancet Haematology
DOI 10.1016/s2352-3026(19)30211-xPMC PMC7008978
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2352-3026(19)30211-x

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Research works printed but not linked: 43

  1. DeZern, 2014, The challenging world of cytopenias: distinguishing myelodysplastic syndromes from other disorders of marrow failure, Oncologist, 19, 735, 10.1634/theoncologist.2014-0056 · DOI
  2. Gondek, 2014, I walk the line: how to tell MDS from other bone marrow failure conditions, Curr Hematol Malig Rep, 9, 389, 10.1007/s11899-014-0224-3 · DOI
  3. Vardiman, 2009, The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes, Blood, 114, 937, 10.1182/blood-2009-03-209262 · DOI
  4. Cogle, 2014, High rate of uncaptured myelodysplastic syndrome cases and an improved method of case ascertainment, Leuk Res, 38, 71, 10.1016/j.leukres.2013.10.023 · DOI
  5. Steensma, 2015, Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes, Blood, 126, 9, 10.1182/blood-2015-03-631747 · DOI · Paper page
  6. Bejar, 2011, Unraveling the molecular pathophysiology of myelodysplastic syndromes, J Clin Oncol, 29, 504, 10.1200/JCO.2010.31.1175 · DOI
  7. Malcovati, 2017, Clinical significance of somatic mutation in unexplained blood cytopenia, Blood, 129, 3371, 10.1182/blood-2017-01-763425 · DOI
  8. Tomasetti, 2017, Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention, Science, 355, 1330, 10.1126/science.aaf9011 · DOI
  9. Tomasetti, 2015, Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions, Science, 347, 78, 10.1126/science.1260825 · DOI · Paper page
  10. Tomasetti, 2013, Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumor initiation, Proc Natl Acad Sci USA, 110, 1999, 10.1073/pnas.1221068110 · DOI
  11. Milholland, 2017, Differences between germline and somatic mutation rates in humans and mice, Nat Commun, 8, 10.1038/ncomms15183 · DOI · Paper page
  12. Xie, 2014, Age-related mutations associated with clonal hematopoietic expansion and malignancies, Nat Med, 20, 1472, 10.1038/nm.3733 · DOI · Paper page
  13. Busque, 2012, Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis, Nat Genet, 44, 1179, 10.1038/ng.2413 · DOI · Paper page
  14. Linder, 1965, Glucose-6-phosphate dehydrogenase mosaicism: utilization as a cell marker in the study of leiomyomas, Science, 150, 67, 10.1126/science.150.3692.67 · DOI
  15. Fialkow, 1967, Clonal origin of chronic myelocytic leukemia in man, Proc Natl Acad Sci USA, 58, 1468, 10.1073/pnas.58.4.1468 · DOI
  16. Zink, 2017, Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly, Blood, 130, 742, 10.1182/blood-2017-02-769869 · DOI · Paper page
  17. Steensma, 2018, Clinical consequences of clonal hematopoiesis of indeterminate potential, Hematology Am Soc Hematol Educ Program, 2018, 264, 10.1182/asheducation-2018.1.264 · DOI
  18. Gondek, 2016, Donor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation, Leukemia, 30, 1916, 10.1038/leu.2016.63 · DOI
  19. Gibson, 2017, Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma, J Clin Oncol, 35, 1598, 10.1200/JCO.2016.71.6712 · DOI · Paper page
  20. Gibson, 2017, Donor-engrafted CHIP is common among stem cell transplant recipients with unexplained cytopenias, Blood, 130, 91, 10.1182/blood-2017-01-764951 · DOI · Paper page
  21. Valent, 2017, Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions, Oncotarget, 8, 73483, 10.18632/oncotarget.19008 · DOI
  22. DeZern, 2019, CHIP, CCUS, and other acronyms: definition, implications, and impact on practice, Am Soc Clin Oncol Educ Book, 39, 400, 10.1200/EDBK_239083 · DOI
  23. Greenberg, 2016, Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes, Blood, 128, 2096, 10.1182/blood-2016-07-728766 · DOI
  24. Valent, 2009, Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS: update and open questions, Eur J Clin Invest, 39, 548, 10.1111/j.1365-2362.2009.02151.x · DOI
  25. Valent, 2012, Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS, Leuk Res, 36, 1
  26. Valent, 2017, Proposed terminology and classification of pre-malignant neoplastic conditions: a consensus proposal, EBioMedicine, 26, 17, 10.1016/j.ebiom.2017.11.024 · DOI
  27. Malcovati, 2013, Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet, Blood, 122, 2943, 10.1182/blood-2013-03-492884 · DOI
  28. Guralnik, 2004, Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia, Blood, 104, 2263, 10.1182/blood-2004-05-1812 · DOI · Paper page
  29. Greenberg, 2017, Myelodysplastic syndromes, version 2.2017, NCCN clinical practice guidelines in oncology, J Natl Compr Canc Netw, 15, 60, 10.6004/jnccn.2017.0007 · DOI
  30. Sekeres, 2019, The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes, Leuk Lymphoma, 10.1080/10428194.2019.1616186 · DOI
  31. Li, 2017, Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists, J Mol Diagn, 19, 4, 10.1016/j.jmoldx.2016.10.002 · DOI
  32. Guidugli, 2017, Clinical utility of gene panel-based testing for hereditary myelodysplastic syndrome/acute leukemia predisposition syndromes, Leukemia, 31, 1226, 10.1038/leu.2017.28 · DOI
  33. Kennedy, 2019, Genetic predisposition to MDS: clinical features and clonal evolution, Blood, 133, 1071, 10.1182/blood-2018-10-844662 · DOI
  34. Ghobrial, 2018, The bone-marrow niche in MDS and MGUS: implications for AML and MM, Nat Rev Clin Oncol, 15, 219, 10.1038/nrclinonc.2017.197 · DOI
  35. Sperling, 2017, The genetics of myelodysplastic syndrome: from clonal haemopoiesis to secondary leukaemia, Nat Rev Cancer, 17, 5, 10.1038/nrc.2016.112 · DOI
  36. Walter, 2012, Clonal architecture of secondary acute myeloid leukemia, N Engl J Med, 366, 1090, 10.1056/NEJMoa1106968 · DOI
  37. Desai, 2018, Somatic mutations precede acute myeloid leukemia years before diagnosis, Nat Med, 24, 1015, 10.1038/s41591-018-0081-z · DOI · Paper page
  38. Kwok, 2015, MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance, Blood, 126, 2355, 10.1182/blood-2015-08-667063 · DOI
  39. Malcovati, 2015, The shadowlands of MDS: idiopathic cytopenias of undetermined significance (ICUS) and clonal hematopoiesis of indeterminate potential (CHIP), Hematology Am Soc Hematol Educ Program, 2015, 299, 10.1182/asheducation-2015.1.299 · DOI
  40. Petrova-Drus, 2017, Clinicopathologic evaluation of cytopenic patients with isolated trisomy 8: a detailed comparison between idiopathic cytopenia of unknown significance and low-grade myelodysplastic syndrome, Leuk Lymphoma, 58, 569, 10.1080/10428194.2016.1203432 · DOI
  41. Neukirchen, 2017, Cytogenetic clonal evolution in myelodysplastic syndromes is associated with inferior prognosis, Cancer, 123, 4608, 10.1002/cncr.30917 · DOI
  42. Steensma, 2018, How I use molecular genetic tests to evaluate patients who have or may have myelodysplastic syndromes, Blood, 132, 1657, 10.1182/blood-2018-06-860882 · DOI
  43. Brunner, 2018, Recent advances in the cellular and molecular understanding of myelodysplastic syndromes: implications for new therapeutic approaches, Clin Adv Hematol Oncol, 16, 56

Cited by

Metadata

Authors
Gondek, L. P., & DeZern, A. E.
Venue
The Lancet Haematology
Publisher
Elsevier BV
Published
2020-01
Volume
7
Issue
1
Pages
e73-e81
ISSN
2352-3026
DOI
10.1016/s2352-3026(19)30211-x
PMC
PMC7008978
Cited by
63
References
17
Language
en
Licence
Funders
US National Institute of Health (K08HL136894 (LPG), R21HL143096 (LPG), 1R03HL136797 (AED), CA006973 (AED))

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review